PCSK9 and coronary artery disorder: The Global Assessment of Plaque Regression With a PCSK9 antibody in a Measured by Intravascular Ultrasound (GLAGOV) trial demonstrated that the addition of the evolocumab to patients with coronary artery disease already pretreated with statins had a favorable effect on progression of coronary atherosclerosis as measured by intravascular ultrasound (IVUS) [38].